Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the most expensive quintile among peers.
Saratoga Health & Biotechnology C SHPCX
- NAV / 1-Day Return 12.84 / +0.86 %
- Total Assets 11.6 Mil
-
Adj. Expense Ratio
- Expense Ratio 3.350%
- Distribution Fee Level High
- Share Class Type Level Load
- Category Health
- Investment Style Large Blend
- Min. Initial Investment 250
- Status Open
- TTM Yield —
- Turnover 58%
USD | NAV as of Apr 19, 2024 | 1-Day Return as of Apr 19, 2024, 10:18 PM GMT+0
Morningstar’s Analysis SHPCX
Will SHPCX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 41.5
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Regeneron Pharmaceuticals Inc | 5.34 | 647,280 | Healthcare |
Cencora Inc | 4.99 | 604,314 | Healthcare |
McKesson Corp | 4.52 | 547,480 | Healthcare |
Amgen Inc | 4.50 | 545,469 | Healthcare |
The Cigna Group | 3.80 | 460,848 | Healthcare |
Cardinal Health Inc | 3.76 | 455,535 | Healthcare |
Elevance Health Inc | 3.76 | 455,135 | Healthcare |
Tenet Healthcare Corp | 3.70 | 448,539 | Healthcare |
Thermo Fisher Scientific Inc | 3.61 | 437,898 | Healthcare |
Intuitive Surgical Inc | 3.56 | 431,872 | Healthcare |